Is big pharma falling back in love with small molecules?

Published

July 6, 2021

Is big pharma falling back in love with small molecules?

New approaches to small-molecule design allow difficult targets to be addressed, such as the G protein-coupled receptors (GPCR) on cell surfaces that are the foundation of intracellular signaling…

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...